Tuesday, July 23, 2019 7:34:03 PM
I posted yesterday that one of the “hidden correlations” which the AI program detected, and which moved our needle, was the failure of 2 recent BACE inhibitor drugs for AD by Novartis and Amgen. The reason this is correlated is that Eisai, where HH is now installed as VP, Global Affairs, Alzheimer’s, has 2 drugs in their AD pipeline in collaboration with Biogen. One is a BACE inhibitor mechanism of action: Elenbecestat. Same as the 2 which just folded. (Looks like a case of barking up the wrong tree, in which case, fold now, and avoid the rush.)
The second drug is BAN2401, a monoclonal antibody (mab). All other “mabs” have folded including Biogen’s own hyped “promising” drug last year - aducanumab. (This is round 2 for Frazier/Ali...)
Here’s what Biogen’s camp has to say about the prospects of these 2 drugs when asked specifically whether they should continue, at today’s earnings cc.
This is why the AI program moved us up. Without these 2 drugs in the pipeline (both in late phases) Eisai is back to square one. That is not at all unusual for a pharma, but, why bring on HH and promote their sleep/epilepsy guy, and commit to the new G2D2 Center in Cambridge, if they are in development stage? And why the big booth with the waterfall at AAIC2019 where they stated they wanted to be the biggest presence in AD going forward and own that space? (Did you see that display? Cool!)
While Eisai remains committed and may have a strategy, read what Biogen is willing to go on record with as their commitment (audience of shareholders..., hmm. Very noncommittal, imo):
This is from the transcript today, link below.
“Evan Seigerman
Hi, guys. Thank you for taking the question and congrats on the progress. One for Al and Michael, so with the recent failure of BACE inhibitor reported by Amgen, Novartis why does Biogen continue to pursue development of Elenbecestat? And generally given the failure of A Beta antibodies, what gives you the confidence that targeting tau is the right approach for AD?
Michael Ehlers
So Evan, why don’t I take the beginning of this? Of course you know, we’re highly aware of all the announcements in and around BACE inhibitors and recent Novartis and Amgen announcement of termination, they’re discontinuing their BACE inhibitors. So we’re highly aware of this.
I would say patient safety is paramount in our clinical trials, including the Mission AD1 and AD2 trials for the BACE inhibitor that is being conducted in collaboration with our collaboration partner Eisai. Those studies have independent data in safety monitoring board that reviews the data regularly from those Phase III studies.
And to-date the DSMB has recommended the studies proceed. They have an ability to look at that data when they want and they are certainly aware of the likewise the safety signals and discontinuation of other programs and they will be assessing it as it goes along.
As BAN2401, I’ll refer back to what Michel commented on earlier, which is that we are in the midst of very thorough analysis of all the ENGAGE and EMERGE data from aducanumab which is an extensive data set and we would like to have a full understanding of that data before we make a specific development decisions on BAN2401.”
Link below.
As far as the EMERGE ENGAGE data they are studying to determine whether to proceed, that is scrutiny of the failure report of aducanumab as discussed earlier in the transcript. As for whether or not to go forward with Elenbecestat, they have a safety signal (in ph3, that is all he’s willing to commit to) and 2 similars just dropped.
That clears the way for an Eisai expedition to find more promising candidates, as the computer’s takeaway. I would have to agree. And, it’s wise.
Transcript
Biogen Inc. (BIIB) CEO Michel Vounatsos on Q2 2019 Results - Earnings Call Transcript $BIIB
https://seekingalpha.com/article/4276771
GLTA,
Bio
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM